What Are the Most Effective New Treatments for Drug-Resistant Parasitic Infections?
Published on: May 19, 2026
What Are The Most Effective New Treatments For Drug-Resistant Parasitic Infections featured image

Introduction

Parasitic infections are diseases caused by organisms that derive nutrients from a host; these organisms are called parasites. Some parasites live inside the host's body and are known as endoparasites (e.g. Plasmodium, which causes malaria). Others live on or outside the body and are known as ectoparasites (e.g. ticks). Parasites derive their energy from the host, which often results in harm to the host. Endoparasites cause greater damage, as their effects extend across multiple organs. Ectoparasite damage is largely limited to the outer tissues of the host's body. The growing drug resistance observed across these parasites is becoming a significant global challenge.

Cellular Characteristics of Parasites

Parasites are eukaryotes, meaning they possess a proper nucleus, a well-structured cellular membrane, and properly functioning organelles. They can be unicellular or multicellular organisms, varying considerably in size and shape.

Unicellular parasites include protozoa,¹ which are single-celled microscopic organisms ranging from 1 to 60 micrometres in size. Multicellular parasites include helminths and arthropods, which range from micrometres to centimetres. Helminths² are worms (e.g. tapeworms, roundworms), while arthropods³ are insects that include ticks and lice.

These infections can spread through direct contact (e.g. Plasmodium via a mosquito bite) or through indirect contact (e.g. giardiasis through contaminated water). Common parasitic infections include malaria, leishmaniasis, giardiasis, trypanosomiasis, and helminthiasis.

Global Impact of Parasitic Infections

Parasitic infections place a serious burden on developing countries. Approximately half a million people die from malaria every year, and millions of dollars are spent annually on vector control spraying to reduce mosquito populations. Giardiasis is a notifiable disease in the United States, affecting around 15 per 100,000 people. Soil-transmitted helminthic infections affect approximately one billion people globally.

Drug Resistance

Emerging drug-resistant strains of malaria, leishmaniasis, and trypanosomiasis are threatening decades of progress in controlling infection spread.

There are several mechanisms through which parasites develop resistance to drugs. Drugs typically act by halting parasite growth at various stages of development; however, repeated exposure and improper drug use can lead to mutations within the parasite. These mutations may reduce drug uptake, increase drug efflux, or cause metabolic modifications, ultimately resulting in therapeutic failure.

Several malarial and leishmaniasis strains have undergone genetic modifications enabling them to survive drug therapy. For example, a mutation in the Pfdhps gene confers resistance against folate antagonists by blocking drug binding to DNA.

Mutations in single, double, or triple genes (Pfmdr1, Pfcrt, Pfmrp, and Pfnhe1) of Plasmodium falciparum result in resistance to chloroquine by actively pumping the drug out of parasite cells.

Metabolic modifications also play an important role, allowing parasites to neutralise a drug before it can act effectively. Resistant strains spread more readily, cause more severe illness, and increase mortality rates. With repeated drug exposure, parasites genetically adapt to survive treatment, meaning drugs cease to be effective while resistant strains continue to circulate within the population.

Common Drug-Resistant Parasitic Infections

The following infections are rapidly developing resistance against standard drug therapies:

  • Plasmodium spp. (malaria): Resistance acquired against artemisinin, chloroquine, and pyrimethamine
  • Leishmania spp.: Resistance emerging against first-line antimonial agents
  • Trypanosomiasis: Resistance reported against melarsoprol and pentamidine
  • Entamoeba histolytica and Giardia spp.: Emerging resistant strains against metronidazole
  • Helminths (hookworms, tapeworms, roundworms): Resistance developing against albendazole and mebendazole

Approaches to Counter Drug-Resistant Parasitic Infections

Several approaches exist to improve treatment outcomes against drug-resistant parasitic infections. The initial step should be promoting the rational use of drugs, including avoiding misuse, improper dosing, and unnecessary repeated exposure.

New drug development typically requires decades to complete, including the establishment of safety and efficacy profiles. Combining different drug classes has shown promising outcomes, as has modifying drug formulations. Incorporating nanotechnology (i.e. reducing drug particle size to the nanometre range) in drug delivery systems has demonstrated improved efficacy, bioavailability, and reduced side effects.

Management of Drug-Resistant Malaria

Artemisinin-based combination therapy (ACT) was introduced to overcome resistance to older antimalarial drugs and remains the cornerstone of malaria treatment. However, due to repeated exposure, resistant strains are emerging in certain regions of Africa and Asia. Current strategies involve adding agents from other drug classes (e.g. pyrimethamine, pyronaridine) or introducing alternative isozymes (drugs with different molecular structures) to improve treatment outcomes.⁴

A novel combination of ganaplacide and lumefantrine is showing promising results in the treatment of resistant malarial strains and is currently in Phase 2 clinical trials.⁵ Although the RTS,S vaccine for malaria is in development, its overall efficacy remains under evaluation.

Management of Giardiasis and Amoebiasis

Metronidazole remains the first-line agent for the treatment of giardiasis and amoebiasis. However, new compounds and analogues are being developed to improve drug potency. Testing of new compounds including nitroimidazole and fexinidazole in giardiasis has shown promising results, though further safety and efficacy evaluation is required.⁶

Management of Leishmaniasis

Although miltefosine remains the first-line agent for the treatment of visceral, mucosal, and cutaneous leishmaniasis, resistance is emerging in some areas. Research is underway to evaluate combination therapies to improve clinical outcomes. Combinations under consideration include liposomal amphotericin B with miltefosine, or miltefosine with paromomycin. These approaches utilise nanoparticle drug delivery to enhance potency and reduce side effects.⁷

Novel agents including the proteasome inhibitor LXE408⁸ and the kinase inhibitor GSK3186899/DDD853651⁹ are currently in clinical trials for the treatment of leishmaniasis.

Management of Trypanosomiasis

Fexinidazole is currently the drug of choice for treating trypanosomiasis. Newer agents, including nifurtimox and eflornithine, offer improved safety and efficacy compared with older-generation drugs, reducing complications and overcoming resistance in these parasites.¹⁰

Management of Helminthic Infections

Combinations of albendazole, mebendazole, ivermectin, and praziquantel are used in the treatment of helminthic infections. Each agent is effective against different species, and the choice of drug depends on the type of infection, the parasite involved, and the side-effect profile of the agent.

FAQs

Are parasitic infections fatal?

Yes, parasitic infections can be fatal, depending on the extent of parasite spread within the body. Malarial infection is the leading cause of parasitic death, followed by leishmaniasis and helminthic infections.

What happens when a parasite enters the body?

When a parasite enters the body, it may affect multiple organs, leading to inflammation, diarrhoea, vomiting, sepsis, or skin rashes. Symptoms depend on the type of parasite and the severity of infection.

When do symptoms of a parasitic infection appear?

Symptoms usually appear within two weeks of infestation; however, some infections may take months to become apparent.

Do parasites resolve on their own?

Some parasitic infections may resolve on their own in individuals with a healthy immune system. It is advisable to consult a primary healthcare provider if any unusual symptoms appear.

Are worm infections life-threatening?

Most worm infections can be treated effectively with medication.

How does a person become infected with parasites?

Some parasites are transmitted through insect bites, such as malaria, leishmaniasis, and trypanosomiasis. Others are transmitted through contaminated food or water, such as giardiasis and amoebiasis. Some worms are acquired through undercooked meat or unwashed raw fruits and vegetables.

Summary

Parasitic infections represent a significant global health burden. Common infections including malaria, leishmaniasis, trypanosomiasis, giardiasis, amoebiasis, and helminthiasis are becoming increasingly resistant to standard treatments, driven by drug misuse and repeated exposure. Combination therapies have demonstrated promising outcomes in enhancing treatment efficacy, and many novel agents as well as nanotechnology-based drug delivery systems are currently under development. Ongoing research aims to identify new molecular targets and develop safe, effective treatments capable of overcoming drug resistance.

References

  1. Yaeger RG. Protozoa: structure, classification, growth, and development. In: Baron S, editor. Medical Microbiology. 4th ed. University of Texas Medical Branch at Galveston; 1996. Available from: http://www.ncbi.nlm.nih.gov/books/NBK8325/
  2. Wakelin D. Helminths: pathogenesis and defenses. In: Baron S, editor. Medical Microbiology. 4th ed. University of Texas Medical Branch at Galveston; 1996. Available from: http://www.ncbi.nlm.nih.gov/books/NBK8191/
  3. Hopla CE, et al. Ectoparasites and classification. Rev Sci Tech. 1994 Dec;13(4):985–1017. Available from: https://doi.org/10.20506/rst.13.4.815
  4. Hanboonkunupakarn B, White NJ. Advances and roadblocks in the treatment of malaria. Br J Clin Pharmacol. 2022 Feb;88(2):374–82. Available from: https://doi.org/10.1111/bcp.14474
  5. Ogutu B, et al. Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, Phase 2 trial. Lancet Infect Dis. 2023 Sep;23(9):1051–61. Available from: https://doi.org/10.1016/S1473-3099(23)00209-8
  6. Bourque DL, et al. Treatment strategies for nitroimidazole-refractory giardiasis: a systematic review. J Travel Med. 2022 Jan;29(1):taab120. Available from: https://doi.org/10.1093/jtm/taab120
  7. Berman J. Liposomal amphotericin B treatment and the leishmaniases. Am J Trop Med Hyg. 2019 Oct;101(4):727–28. Available from: https://doi.org/10.4269/ajtmh.19-0568
  8. Nagle A, et al. Discovery and characterization of clinical candidate LXE408 as a kinetoplastid-selective proteasome inhibitor for the treatment of leishmaniases. J Med Chem. 2020 Oct;63(19):10773–81. Available from: https://doi.org/10.1021/acs.jmedchem.0c00499
  9. Thomas MG, et al. Identification of GSK3186899/DDD853651 as a preclinical development candidate for the treatment of visceral leishmaniasis. J Med Chem. 2019 Feb;62(3):1180–202. Available from: https://doi.org/10.1021/acs.jmedchem.8b01218
  10. Hidalgo J, et al. Efficacy and toxicity of fexinidazole and nifurtimox plus eflornithine in the treatment of African trypanosomiasis: a systematic review. Cureus. 2021 Aug;13(8):e16881. Available from: https://doi.org/10.7759/cureus.16881
Share

Taleeb Khan

Pharm-D

arrow-right